Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Seven patients with CFRD were fed 1,000-kcal liquid mixed meals. Three study conditions were administered in random order on separate mornings: 1) no premeal diabetes medication, 2) insulin lispro, 0.1 unit/kg body wt premeal and 3) repaglinide 1 mg premeal. Glucose and insulin levels were measured every 20 min for 5 h. RESULTS: CONCLUSIONS: In response to subcutaneous insulin lispro, postprandial glucose excursion was significantly diminished and insulin secretion was enhanced compared with a control meal in which no medication was given to patients with CFRD. The oral agent repaglinide resulted in lesser corrections in these parameters. Neither drug completely normalized glucose or insulin levels, suggesting that the doses chosen for this study were suboptimal. Placebo-controlled longitudinal studies comparing the effectiveness of repaglinide and insulin on glucose metabolic control as well as overall nutrition and body weight are needed to help determine optimal medical treatment of CFRD.
|
Authors | A Moran, J Phillips, C Milla |
Journal | Diabetes care
(Diabetes Care)
Vol. 24
Issue 10
Pg. 1706-10
(Oct 2001)
ISSN: 0149-5992 [Print] United States |
PMID | 11574430
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Blood Glucose
- Carbamates
- Hypoglycemic Agents
- Insulin
- Insulin Lispro
- Piperidines
- repaglinide
|
Topics |
- Adult
- Blood Glucose
(metabolism)
- Carbamates
(administration & dosage, therapeutic use)
- Cystic Fibrosis
(complications)
- Diabetes Mellitus
(blood, etiology)
- Female
- Food
- Humans
- Hypoglycemia
(etiology)
- Hypoglycemic Agents
(administration & dosage, therapeutic use)
- Insulin
(administration & dosage, analogs & derivatives, blood, therapeutic use)
- Insulin Lispro
- Male
- Piperidines
(administration & dosage, therapeutic use)
|